Skip to main content
SUNDRUG CO.,LTD. logo

SUNDRUG CO.,LTD. — Investor Relations & Filings

Ticker · 9989 ISIN · JP3336600006 T Wholesale and retail trade
Open in API
Filings indexed 60 across all filing types
Latest filing 2024-02-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 9989

About SUNDRUG CO.,LTD.

https://www.sundrug.co.jp/

SUNDRUG CO.,LTD. operates a chain of drugstores, dispensing pharmacies, and discount stores. The company's activities are organized into two primary segments: the Drug Store Business and the Discount Store Business. It engages in the retail and wholesale of a wide range of products, including pharmaceuticals, cosmetics, and daily necessities. In addition to its corporate-owned stores, SUNDRUG provides products and business guidance to franchise and voluntary chain stores. The company manages various store formats and brands within its group and also operates an e-commerce platform.

Recent filings

Filing Released Lang Actions
四半期報告書－第61期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Sundrug Co., Ltd. covering the third quarter of the 61st fiscal year (period ending December 31, 2023). It contains detailed financial statements, including the consolidated balance sheet and management's analysis of financial results. This fits the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is extremely short (593 characters) and contains a table structure typical of a cover page for a regulatory filing in Japan. Key elements include: '【提出書類】確認書' (Filing Document: Confirmation Document), '【根拠条文】金融商品取引法第24条の４の８第１項' (Legal Basis: Article 24-4-8, Paragraph 1 of the Financial Instruments and Exchange Act), and a confirmation statement regarding the appropriateness of the '四半期報告書' (Quarterly Report) for the period ending September 30, 2023, signed by the CEO. This document is a formal certification or confirmation related to a quarterly report, not the quarterly report itself. Since it is a formal certification/confirmation related to a specific periodic report (Quarterly Report), it aligns best with the 'Interim / Quarterly Report' (IR) category, as it is intrinsically linked to the content of that report, or potentially a Regulatory Filing (RNS) if a more specific confirmation code isn't available. Given the context of confirming the 'Quarterly Report' (四半期報告書), the most appropriate classification among the provided options is 'IR' (Interim / Quarterly Report), as this document is a mandatory accompanying certification for that specific filing type in Japan (often filed alongside or immediately after the Q-report). However, because this is explicitly a 'Confirmation Document' (確認書) and not the full report, and given its brevity, it could also be argued as a Regulatory Filing (RNS). Since the core subject matter is the Quarterly Report, and 'IR' covers comprehensive reports for shorter periods, I will classify it as IR, acknowledging the confirmation aspect.
2023-11-14 Japanese
四半期報告書－第61期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Sundrug Co., Ltd. with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the consolidated balance sheet, for the second quarter of the 61st fiscal period (ending September 30, 2023). It is a comprehensive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). Q2 2024
2023-11-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It specifically confirms the accuracy of the contents of the Quarterly Report (Shihanki Hokokusho) for the first quarter of the 61st fiscal period. Since this is a formal regulatory filing confirming the validity of a financial report rather than the report itself, and it does not fit into the specific categories for earnings releases or full reports, it is classified as a Regulatory Filing.
2023-08-14 Japanese
四半期報告書－第61期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Sundrug Co., Ltd. in Japan. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 61st fiscal year (April 1, 2023, to June 30, 2023). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2023-08-14 Japanese
内部統制報告書－第60期(2022/04/01－2023/03/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act in Japan. It details the company's framework, scope, and results regarding internal controls over financial reporting. This type of standalone regulatory report concerning audit-related internal control assessments falls under the 'Audit Report / Information' category.
2023-06-26 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.